CRVO · XBRL financial data
CervoMed financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (CRVO's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 7,145 | 9,738 | 4,007 |
| Research and development | 9,428 | 8,499 | 7,237 | 8,438 | 18,798 | 21,817 |
| General and administrative | 6,444 | 7,445 | 8,735 | 6,519 | 9,167 | 10,484 |
| Total operating expenses | — | — | 3,476 | 14,958 | 27,965 | 32,301 |
| Operating income (loss) | (15,975) | (24,677) | (15,972) | (7,813) | (18,227) | (28,295) |
| Interest income | — | — | 62 | 219 | 1,937 | 1,337 |
| Interest expense | — | — | 1 | 0 | — | — |
| Other income (expense) | — | — | (2,389) | 5,422 | (1) | (8) |
| Income tax expense (benefit) | (1,675) | (444) | 0 | — | — | 0 |
| Net income (loss) | (14,185) | (24,096) | (15,591) | (2,172) | (16,291) | (26,966) |
| Earnings per share, basic USD per share | (0.30) | (0.25) | (7.65) | (0.82) | (2.02) | (2.98) |
| Earnings per share, diluted USD per share | 53,831,973.00 | 97,626,748.00 | 2,038,891.00 | — | — | — |
| Weighted average shares, basic thousands of shares | — | — | 518 | 2,661 | 8,073 | 9,042 |
- † Share count changed about 1/50 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 3x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (CRVO's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 18,516 | 37,314 | 10,114 | 7,793 | 8,999 | 8,235 |
| Marketable securities | — | 0 | 12,409 | 0 | 29,923 | 12,629 |
| Marketable securities, non-current | — | — | — | 0 | — | — |
| Prepaid and other current assets | — | — | 64 | 1,257 | 1,905 | 1,267 |
| Total current assets | 18,776 | 37,824 | 22,635 | 9,965 | 43,082 | 22,879 |
| Property and equipment, net | 149 | 0 | — | — | — | — |
| Right-of-use asset | 149 | 0 | — | — | — | — |
| Total assets | 27,730 | 37,839 | 22,635 | 9,973 | 43,082 | 22,879 |
| Accounts payable | 546 | 947 | 1,128 | 662 | 1,511 | 1,454 |
| Total current liabilities | 2,436 | 2,928 | — | — | 3,879 | 4,656 |
| Lease liability, non-current | 36 | 0 | — | — | — | — |
| Total liabilities | 2,915 | 2,928 | 2,417 | 2,596 | 3,879 | 4,656 |
| Accumulated deficit | (105,909) | (130,005) | (145,597) | (54,441) | (70,731) | (97,698) |
| Total stockholders' equity | 24,814 | 34,911 | 20,218 | 7,377 | 39,202 | 18,223 |
| Total liabilities and equity | 27,730 | 37,839 | 22,635 | 9,973 | 43,082 | 22,879 |
| Common shares outstanding (cover page) thousands of shares | 101,904 | 101,925 | 2,040 | 6,170 | 8,703 | 9,259 |
- † Share count changed about 1/50 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 3x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (CRVO's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (14,185) | (24,096) | (15,591) | (2,172) | (16,291) | (26,966) |
| Stock-based compensation | 736 | 897 | 928 | 408 | 1,406 | 1,449 |
| Depreciation and amortization | 103 | 93 | 0 | — | — | — |
| Net cash from operating activities | (13,553) | (14,502) | (14,969) | (7,450) | (16,531) | (23,450) |
| Net cash from investing activities | 0 | 4 | (12,236) | 0 | (28,661) | 18,097 |
| Proceeds from issuing common stock | 10,827 | 31,094 | 0 | 810 | 46,399 | — |
| Net cash from financing activities | 17,891 | 33,296 | 5 | 11,149 | 46,399 | 4,589 |
| Net change in cash | 4,338 | 18,798 | (27,200) | 3,699 | 1,207 | (764) |
- † Share count changed about 1/50 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 3x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| CervoMed | 22,463 | 0 | (6,918)* | 15.1M | 3.6 quarters | 10-QJun 30, 2026 |
| Atara Biotherapeutics | 3,221 | 630 | (3,338)* | 10.0M | 3.0 quarters | 10-QJun 30, 2026 |
| Actuate Therapeutics | 4,426 | not reported | (4,405)* | 24.0M | 1.0 quarters | 10-QJun 30, 2026 |
| BriaCell Therapeutics | 9,852 | not reported | (5,959)* | 8.7M | 3.4 quarters | 10-KJul 31, 2026 |
| Lite Strategy | 5,706 | not reported | (1,164)* | 30.4M | 4.9 quarters | 10-KJun 30, 2026 |
| Abvc Biopharma | 32 | not reported | (244)* | 26.7M | 0.4 quarters | 10-QJun 30, 2026 |
| Karyopharm Therapeutics | 54,980 | 33,432 | (24,931)* | 22.7M | 2.6 quarters | 10-QJun 30, 2026 |
| Actinium Pharmaceuticals | 36,473 | 35,000 | (5,179)* | 31.4M | 7.0 quarters | 10-QJun 30, 2026 |
| Fortress Biotech | 196,576 | 18,718 | (59,277)* | 33.3M | 3.3 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.